Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Blood neurofilament light as a potential endpoint in Phase 2 studies in MS.

Sormani MP, Haering DA, Kropshofer H, Leppert D, Kundu U, Barro C, Kappos L, Tomic D, Kuhle J.

Ann Clin Transl Neurol. 2019 May 28;6(6):1081-1089. doi: 10.1002/acn3.795. eCollection 2019 Jun.

2.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

3.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

4.

Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins.

Hamuro L, Kijanka G, Kinderman F, Kropshofer H, Bu DX, Zepeda M, Jawa V.

J Pharm Sci. 2017 Oct;106(10):2946-2954. doi: 10.1016/j.xphs.2017.05.030. Epub 2017 May 31. Review.

PMID:
28576695
5.

The effects of intrathecal rituximab on biomarkers in multiple sclerosis.

Topping J, Dobson R, Lapin S, Maslyanskiy A, Kropshofer H, Leppert D, Giovannoni G, Evdoshenko E.

Mult Scler Relat Disord. 2016 Mar;6:49-53. doi: 10.1016/j.msard.2016.01.001. Epub 2016 Jan 19.

PMID:
27063622
6.

T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.

Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS.

Clin Immunol. 2013 Dec;149(3):534-55. doi: 10.1016/j.clim.2013.09.006. Epub 2013 Sep 25. Review.

7.

A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.

Bailey L, Moreno L, Manigold T, Krasniqi S, Kropshofer H, Hinton H, Singer T, Suter L, Hansel TT, Mitchell JA.

J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):231-239. doi: 10.1016/j.vascn.2012.12.003. Epub 2012 Dec 29.

PMID:
23280407
8.

Taking immunogenicity assessment of therapeutic proteins to the next level.

Büttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, Kramer D, Kropshofer H, Lloyd P, Lubiniecki A, Krause R, Mire-Sluis A, Platts-Mills T, Ragheb JA, Reipert BM, Schellekens H, Seitz R, Stas P, Subramanyam M, Thorpe R, Trouvin JH, Weise M, Windisch J, Schneider CK.

Biologicals. 2011 Mar;39(2):100-9. doi: 10.1016/j.biologicals.2011.01.006. Epub 2011 Feb 24.

PMID:
21353596
9.

The safety and side effects of monoclonal antibodies.

Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ.

Nat Rev Drug Discov. 2010 Apr;9(4):325-38. doi: 10.1038/nrd3003. Epub 2010 Mar 22. Review.

PMID:
20305665
10.

Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout.

Mueller R, Karle A, Vogt A, Kropshofer H, Ross A, Maeder K, Mahler HC.

J Pharm Sci. 2009 Oct;98(10):3548-61. doi: 10.1002/jps.21672.

PMID:
19226629
11.

Overview of cell-based tools for pre-clinical assessment of immunogenicity of biotherapeutics.

Kropshofer H, Singer T.

J Immunotoxicol. 2006 Sep 1;3(3):131-6. doi: 10.1080/15476910600845625.

PMID:
18958693
12.

Transport of Streptococcus pneumoniae capsular polysaccharide in MHC Class II tubules.

Stephen TL, Fabri M, Groneck L, Röhn TA, Hafke H, Robinson N, Rietdorf J, Schrama D, Becker JC, Plum G, Krönke M, Kropshofer H, Kalka-Moll WM.

PLoS Pathog. 2007 Mar;3(3):e32.

13.

A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope.

Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H.

Cancer Res. 2005 Nov 1;65(21):10068-78.

14.

Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.

Röhn TA, Schadendorf D, Sun Y, Nguyen XD, Roeder D, Langen H, Vogt AB, Kropshofer H.

Eur J Immunol. 2005 Oct;35(10):2826-39.

15.

Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.

Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D.

Clin Cancer Res. 2005 Jul 15;11(14):5241-7.

16.

High-sensitivity miniaturized immunoassays for tumor necrosis factor alpha using microfluidic systems.

Cesaro-Tadic S, Dernick G, Juncker D, Buurman G, Kropshofer H, Michel B, Fattinger C, Delamarche E.

Lab Chip. 2004 Dec;4(6):563-9. Epub 2004 Nov 10.

PMID:
15570366
17.

Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization.

Röhn TA, Boes M, Wolters D, Spindeldreher S, Müller B, Langen H, Ploegh H, Vogt AB, Kropshofer H.

Nat Immunol. 2004 Sep;5(9):909-18. Epub 2004 Aug 22.

PMID:
15322540
18.

DM loss in k haplotype mice reveals isotype-specific chaperone requirements.

Koonce CH, Wutz G, Robertson EJ, Vogt AB, Kropshofer H, Bikoff EK.

J Immunol. 2003 Apr 1;170(7):3751-61.

19.
20.
21.

Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes.

Kropshofer H, Spindeldreher S, Röhn TA, Platania N, Grygar C, Daniel N, Wölpl A, Langen H, Horejsi V, Vogt AB.

Nat Immunol. 2002 Jan;3(1):61-8. Epub 2001 Dec 17.

PMID:
11743588
23.

Functional HLA-DM on the surface of B cells and immature dendritic cells.

Arndt SO, Vogt AB, Markovic-Plese S, Martin R, Moldenhauer G, Wölpl A, Sun Y, Schadendorf D, Hämmerling GJ, Kropshofer H.

EMBO J. 2000 Mar 15;19(6):1241-51.

24.

The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.

Kropshofer H, Hämmerling GJ, Vogt AB.

Immunol Rev. 1999 Dec;172:267-78. Review.

PMID:
10631952
25.

Antigen processing and presentation--towards the millennium.

Hämmerling GJ, Vogt AB, Kropshofer H.

Immunol Rev. 1999 Dec;172:5-9. Review. No abstract available.

PMID:
10631932
26.

Quality control of MHC class II associated peptides by HLA-DM/H2-M.

Vogt AB, Arndt SO, Hämmerling GJ, Kropshofer H.

Semin Immunol. 1999 Dec;11(6):391-403. Review.

PMID:
10625593
27.

Drug-induced inhibition of insulin recognition by T-cells: the antirheumatic drug aurothiomalate inhibits MHC binding of insulin peptide.

Takahashi K, Kropshofer H, Vogt AB, Gleichmann E, Griem P.

Mol Immunol. 1998 Dec;35(17):1081-7.

PMID:
10395197
28.

HLA-DM - an endosomal and lysosomal chaperone for the immune system.

Vogt AB, Kropshofer H.

Trends Biochem Sci. 1999 Apr;24(4):150-4. Review.

PMID:
10322421
29.

Identification of destabilizing residues in HLA class II-selected bacteriophage display libraries edited by HLA-DM.

Raddrizzani L, Bono E, Vogt AB, Kropshofer H, Gallazzi F, Sturniolo T, Hämmerling GJ, Sinigaglia F, Hammer J.

Eur J Immunol. 1999 Feb;29(2):660-8.

30.

Binding affinity independent contribution of peptide length to the stability of peptide-HLA-DR complexes in live antigen presenting cells.

Siklodi B, Vogt AB, Kropshofer H, Falcioni F, Molina M, Bolin DR, Campbell R, Hämmerling GJ, Nagy ZA.

Hum Immunol. 1998 Aug;59(8):463-71.

PMID:
9712349
31.

A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules.

Kropshofer H, Vogt AB, Thery C, Armandola EA, Li BC, Moldenhauer G, Amigorena S, Hämmerling GJ.

EMBO J. 1998 Jun 1;17(11):2971-81.

32.

Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome.

Faigle W, Raposo G, Tenza D, Pinet V, Vogt AB, Kropshofer H, Fischer A, de Saint-Basile G, Amigorena S.

J Cell Biol. 1998 Jun 1;141(5):1121-34.

33.

HLA-DM stabilizes empty HLA-DR molecules in a chaperone-like fashion.

vogt AB, Moldenhauer G, Hämmerling GJ, Kropshofer H.

Immunol Lett. 1997 Jun 1;57(1-3):209-11.

PMID:
9232453
34.

How HLA-DM affects the peptide repertoire bound to HLA-DR molecules.

Vogt AB, Kropshofer H, Hämmerling GJ.

Hum Immunol. 1997 May;54(2):170-9. Review.

PMID:
9297535
35.

HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH.

Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB.

Immunity. 1997 Mar;6(3):293-302.

36.

How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest?

Kropshofer H, Hämmerling GJ, Vogt AB.

Immunol Today. 1997 Feb;18(2):77-82. Review.

PMID:
9057358
37.

Selection of the MHC class II-associated peptide repertoire by HLA-DM.

Arndt SO, Vogt AB, Hämmerling GJ, Kropshofer H.

Immunol Res. 1997;16(3):261-72. Review.

PMID:
9379076
38.

Editing of the HLA-DR-peptide repertoire by HLA-DM.

Kropshofer H, Vogt AB, Moldenhauer G, Hammer J, Blum JS, Hämmerling GJ.

EMBO J. 1996 Nov 15;15(22):6144-54.

39.

Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.

Vogt AB, Kropshofer H, Moldenhauer G, Hämmerling GJ.

Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9724-9.

40.

Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion.

Kipriyanov SM, Little M, Kropshofer H, Breitling F, Gotter S, Dübel S.

Protein Eng. 1996 Feb;9(2):203-11.

PMID:
9005442
41.

Self-release of CLIP in peptide loading of HLA-DR molecules.

Kropshofer H, Vogt AB, Stern LJ, Hämmerling GJ.

Science. 1995 Nov 24;270(5240):1357-9.

PMID:
7481823
42.

Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.

Vogt AB, Stern LJ, Amshoff C, Dobberstein B, Hämmerling GJ, Kropshofer H.

J Immunol. 1995 Nov 15;155(10):4757-65.

PMID:
7594477
43.
44.

Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides.

Vogt AB, Kropshofer H, Kalbacher H, Kalbus M, Rammensee HG, Coligan JE, Martin R.

J Immunol. 1994 Aug 15;153(4):1665-73.

PMID:
7519208
45.

Association of HLA and multiple sclerosis.

Martin R, Vogt AB, Kropshofer H, Lichtenfels R.

Behring Inst Mitt. 1994 Jul;(94):158-70. Review.

PMID:
7998908
46.

Self-peptides from four HLA-DR alleles share hydrophobic anchor residues near the NH2-terminal including proline as a stop signal for trimming.

Kropshofer H, Max H, Halder T, Kalbus M, Muller CA, Kalbacher H.

J Immunol. 1993 Nov 1;151(9):4732-42.

PMID:
8409432
47.

Characterization of peptides bound to extracellular and intracellular HLA-DR1 molecules.

Max H, Halder T, Kropshofer H, Kalbus M, Müller CA, Kalbacher H.

Hum Immunol. 1993 Nov;38(3):193-200.

PMID:
8106277
48.

Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia.

Bühring HJ, Herbst R, Kostka G, Bossenmaier B, Bartke I, Kropshofer H, Kalbacher H, Busch FW, Müller CA, Schlessinger J, et al.

Cancer Res. 1993 Sep 15;53(18):4424-31.

49.
50.

Self-peptide released from class II HLA-DR1 exhibits a hydrophobic two-residue contact motif.

Kropshofer H, Max H, Müller CA, Hesse F, Stevanovic S, Jung G, Kalbacher H.

J Exp Med. 1992 Jun 1;175(6):1799-803.

Supplemental Content

Loading ...
Support Center